Schlessinger J.Ligand-induced,receptor-mediated dimerization and activation of EGF receptor [J].Cell,2002,110(6):669-672.
[6]
Herbst RS,Heymach JV,Lippman SM.Lung cancer [J].N Engl J ed,2008,359(13):1367-1380.
[7]
Rosell R,Carcereny E,Gervais R,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer(EURTAC): a multicentre,open-label,randomised phase 3 trial [ J].Lancet Oncol,2012,13(3): 239-246.
[8]
Tiseo M,Gridelli C,Cascinu S,et al. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer(NSCLC):：data report from Italy [J].Lung Cancer,2009,64(2): 199-206.
[9]
Zhou C,Wu YL,Chen G,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802): a multicentre,open-label,randomised,phase 3 study [J]. Lancet Oncol,2011,12(8): 735-742.
[10]
Mok TS,Wu YL,Thongprasert S,et al．Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J].N Engl J Med,2009,361(10):947-957．
Sun Y,Shi Y,Zhang L,et al.A randomized,double-blind phase 3 study of iconitib versus gefitinib in patients with advanced non-small cell lung cancer(NSCLC) previously treated with chemotherapy(ICOGEN)[J].J Clin Oncol,2011,29(suppl):Abstr 7522.
[13]
Tan F,Shen X,Wang D,et al.Icotinib (BPI-2009H),a novel EGFR tyrosine kinase inhibitor,displays potent efficacy in preclinical studies [J].Lung Cancer,2012,76(2):177-182.
